Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CD47 checkpoint data supercharge Stanford spinout IPO

A News to this article was published on 01 October 2018

This article has been updated

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 26 September 2018

    This News Analysis described ongoing trials for drugs targeting CD47. However, the article omitted mention of a clinical trial with an anti-CD47 antibody from Tioma Therapeutics, which was terminated on the death of the first patient dosed. This fatality, potentially ascribed to red cell agglutination, may have some bearing on other trials with anti-CD47 antibodies.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. CD47 checkpoint data supercharge Stanford spinout IPO. Nat Biotechnol 36, 671–672 (2018). https://doi.org/10.1038/nbt0818-671

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing